HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIR Expert Panel Reaches Tentative Decision On Benzophenones, Final On Methylisothiazolinone

Executive Summary

At its 14-15 September virtual meeting, the Cosmetic Ingredient Review’s Expert Panel issued five final ingredient reports, four tentative reports, and insufficient data announcements for seven ingredients or ingredient groups, including silicates and 60 red algae ingredients.

You may also be interested in...



CIR ‘Watchdog’ Women’s Voices For The Earth To Remain On Guard In 2021

NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.

Cosmetic Ingredient Review Finalizes 2021 Priorities; Data Requested

CIR’s 2021 priorities list is heavy with skin-care ingredients and builds on recent natural ingredient review work. The group encourages stakeholders to submit data as soon as possible to help inform its development of scientific literature reviews.

At US FDA, Adding ‘Effective’ Staff For Overhauled OTC Monograph Program ‘Really Takes Time’

CDER’s Office of Nonprescription Drugs is “hitting the deck running’” hiring and training staff following passage of OTC monograph reform with user fees to support adding staff and a reshuffling earlier in 2020, says Peter Stein, Office of New Drugs director.

Related Content

Topics

UsernamePublicRestriction

Register

RS150501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel